A diabetes drug can increase a person's risk of bladder cancer, researchers have found.
The anti-diabetic drug pioglitazone helps to control blood sugar levels in patients with type 2 diabetes.
But new research, published in The BMJ, has found that taking the drug is linked to a 63% increased risk of bladder cancer.
Figures from the Health and Social Care Information Centre show 1.18 million prescriptions for pioglitazone hydrochloride were dispensed in England in 2014.
Researchers wanted to assess the drug after a number of bladder cancer cases were identified among people taking the drug in a trial in 2005. Since then different studies have reported contradictory findings on the subject.
They set out to compare pioglitazone to other anti-diabetic drugs.
Experts identified 145,806 patients from the UK Clinical Practice Research Database newly treated with anti-diabetic drugs between January 2000 - when pioglitazone and another medicine from the same class of drug called rosiglitazone first entered the UK market - and July 2013, with follow-up until July 2014.
Overall, 622 of these patients received a diagnosis of bladder cancer during the follow-up period.
The team of Canadian-based researchers found that compared to other anti-diabetic drugs, pioglitazone was associated with an increased risk of bladder cancer. The risk heightened with increasing duration of use and dose, they found.
No increased risk was found for rosiglitazone - the drug was withdrawn from use in 2010 due to an increased risk of cardiovascular disorders, including heart attack and heart failure.
"In this large population-based cohort study with up to 14.5 years of follow-up, pioglitazone was associated with an overall 63% increased risk of incident bladder cancer," they wrote.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here